SK Hynix Considers U.S. ADR Listing to Boost Shareholder Value Amid Rising AI Chip Demand 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
SoftBank Eyes Switch Inc as It Pushes Deeper Into AI Data Center Expansion 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
SoftBank Shares Slide as Oracle’s AI Spending Plans Fuel Market Jitters 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
RALEIGH, N.C., April 17, 2018 -- Syneos HealthTM (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO and CCO (Contract Commercial Organization), will release its first quarter 2018 financial results on Wednesday, May 9, 2018, prior to its earnings call at 8:00 a.m. EDT.
Participants may access the conference call live via webcast on the Investor Relations section of the Syneos Health website at investor.syneoshealth.com. To participate via telephone, please dial +1 877 930 8058 within the United States or +1 253 336 7551 outside the United States, approximately 15 minutes prior to the scheduled start time. The conference ID for the call is 6394229.
A webcast replay will be available on the Investor Relations section of the Syneos Health website at investor.syneoshealth.com after 1:00 p.m. on May 9. In addition, an audio replay will be available for one week following the call and will be accessible by dialing +1 855 859 2056 within the United States or +1 404 537 3406 outside the United States. The replay ID is 6394229.
About Syneos Health
Syneos Health (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through the merger of two industry leading companies – INC Research and inVentiv Health – we bring together more than 21,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to lifeTM visit syneoshealth.com.
| Investor Relations Contact: | Press/Media Contact: | ||||
| Ronnie Speight | Danielle DeForge | ||||
| Vice President, Investor Relations | Senior Director, External Communications | ||||
| +1 919 745 2745 | +1 781 425 2624 | ||||
| [email protected] | [email protected] |
